ixekizumab news

All news on ixekizumab (also known as Taltz): plants, production capacities, investments and involved companies.

31 August 2026

Eli Lilly: Taltz plus Zepbound sustain improved psoriatic and metabolic outcomes at 52 weeks

Combination maintained or deepened psoriasis and psoriatic arthritis responses and reduced systemic inflammation while improving metabolic measures including BMI and HbA1c at one year versus Taltz alone.
28 March 2026

Lilly: Taltz + Zepbound superior to Taltz alone in psoriatic arthritis with obesity

Phase 3b TOGETHER‑PsA: combination therapy improved ACR50, MDA, fatigue, function, QoL and cardiometabolic markers; 36‑week primary endpoint met (ACR50+≥10% weight loss 31.7% vs 0.8%).

Who will be producing ixekizumab in the future?

Find out with chemXplore Alpha

Learn more